SCHEMBL1645151

SCHEMBL1645151

CN(C)C(=O)Cc1cc(O)ccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
CA12 O43570 3/20 0.47
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
CA7 P43166 3/20 0.47
CA9 Q16790 3/20 0.47
CA14 Q9ULX7 3/20 0.47
TSHR P16473 1/20 0.47
LTB4R Q15722 1/20 0.45
LTB4R2 Q9NPC1 1/20 0.45
ALOX5 P09917 1/20 0.43
PTGS2 P35354 1/20 0.43
EGFR P00533 3/20 0.42
LCK P06239 3/20 0.42
TDP1 Q9NUW8 3/20 0.40
MAPT P10636 3/20 0.40
RGS12 O14924 1/20 0.40
CAMKK2 Q96RR4 1/20 0.40
NOX4 Q9NPH5 1/20 0.40
MEN1 O00255 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1647247 0.81 POLB (0.44) ALDH1A1CA12CA1CA2CA7
SCHEMBL3133362 0.81 EGFR (0.47) ALDH1A1CA12CA1CA2CA7
SCHEMBL21464343 0.80 CA2 (0.55) ALDH1A1CA12CA1CA2CA7
SCHEMBL39010 0.78 CA12 (0.57) ALDH1A1CA12CA1CA2CA7
SCHEMBL28126806 0.78 CA12 (0.57) ALDH1A1CA12CA1CA2CA7
SCHEMBL5162216 0.78 SLC6A2 (0.40) CA12CA1CA2CA7CA9
SCHEMBL11276801 0.78 EGFR (0.54) ALDH1A1CA12CA1CA2CA7
SCHEMBL7308754 0.77 ALDH1A1 (0.52) ALDH1A1CA12CA1CA2CA7
SCHEMBL27517848 0.77 CA12 (0.55) ALDH1A1CA12CA1CA2CA7
SCHEMBL3873135 0.77 CA12 (0.55) ALDH1A1CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188022-A1 PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2025-06-12 US disclosed
WO-2023148783-A1 PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-08-10 WO disclosed
US-20120208882-A1 Organic Compounds DANAHAY HENRY LUKE (GB) 2012-08-16 US disclosed
EP-2305639-A2 Organic compounds Novartis AG (CH) 2011-04-06 EP disclosed
EP-2253612-A1 Organic compounds Novartis AG (CH) 2010-11-24 EP disclosed
US-20090203777-A1 ORGANIC COMPOUNDS MAAS, JANET CATHERINE (GB) 2009-08-13 US disclosed
US-4021472-A ANTIPLASMIN AND ANTITRYPSIN ONO PHARMACEUTICAL CO., LTD. (JA) 1977-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208882-A1 Organic Compounds CFTR, OTC, ASIC1 ALDH1A1 489/4885CA12 69/4885CA1 781/4885
US-20250188022-A1 PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES TPMT, ADH1C, ADH1A ALDH1A1 256/4885CA12 2205/4885CA1 700/4885
US-20090203777-A1 ORGANIC COMPOUNDS CFTR, OTC, ASIC1 ALDH1A1 489/4885CA12 69/4885CA1 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.